Naratuximab emtansine (IMGN529) is a CD37-targeted antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody linked to the microtubule-disrupting agent DM1. This compound demonstrates high affinity and specificity to CD37, facilitating the internalization, processing, and intracellular release of DM1. The functional activity of DM1 enables it to induce cell cycle arrest and apoptosis by disrupting microtubule assembly.

Naratuximab emtansine (IMGN529) 在单独使用时（0.125 nM, 24 h），能够在DLBCL细胞系中引发半胱氨酸3/7的活化，并且在与rituximab（2 nM）联合应用下，可显著增强这一效果，导致PARP裂解水平上升。此外，Naratuximab emtansine（IMGN529）在0-3 ng/mL的浓度范围内，对U-2932及SU-DHL-4细胞系表现出剂量依赖的抗体依赖的细胞介导的细胞毒性（ADCC）活性。

在多发性骨髓瘤治疗中，Indatuximab ravtansine（5.3-21.2 mg/kg；静脉注射；一次）通过抑制肿瘤的生长，有效地提高了宿主的存活率。